Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raymond Cross

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
JMIR Research Protocols|December 15, 2022
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and Persistence With Inflammatory Bowel Disease Therapy (ASSIST Study): Protocol for a Randomized Controlled TrialJordan Axelrad, Millie Long, Sara Horst, et al.
The American Journal of Gastroenterology|July 18, 2023
P035 Ozanimod for Moderate-to-Severe Ulcerative Colitis: North American Population Results During Induction and Maintenance in the Phase 3 True North StudyDavid Hudesman, Millie Long, Douglas Wolf, et al.
The American Journal of Gastroenterology|July 18, 2023
P038 Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple SclerosisMillie Long, Raymond Cross, Jonathan Calkwood, et al.
Gastroenterology|April 14, 2019
Inflammatory Bowel Disease Care Referral PathwayJami Kinnucan, David Binion, Raymond Cross, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 6, 2014
Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitisMark T Osterman, Faten N Aberra, Raymond Cross, et al.
Inflammatory Bowel Diseases|March 15, 2020
Endoscopic and Histological Assessment, Correlation, and Relapse in Clinically Quiescent Ulcerative Colitis (MARQUEE)Mark T Osterman, Frank I Scott, Franz F Fogt, et al.
Alimentary Pharmacology & Therapeutics|August 4, 2020
A phase 2B randomised trial of hyperbaric oxygen therapy for ulcerative colitis patients hospitalised for moderate to severe flaresParambir S Dulai, Laura E Raffals, David Hudesman, et al.
Alimentary Pharmacology & Therapeutics|November 15, 2022
Crohn's disease shared decision making intervention leads to more patients choosing combination therapy: a cluster randomised controlled trialYaara Zisman-Ilani, Kimberly D Thompson, Lori S Siegel, et al.
Inflammatory Bowel Diseases|August 26, 2021
The Development and Initial Findings of A Study of a Prospective Adult Research Cohort with Inflammatory Bowel Disease (SPARC IBD)Laura E Raffals, Sumona Saha, Meenakshi Bewtra, et al.
The Lancet. Gastroenterology & Hepatology|January 20, 2020
Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease GroupBo Shen, Gursimran Kochhar, Udayakumar Navaneethan, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
JMIR Research Protocols|December 15, 2022
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and Persistence With Inflammatory Bowel Disease Therapy (ASSIST Study): Protocol for a Randomized Controlled TrialJordan Axelrad, Millie Long, Sara Horst, et al.
The American Journal of Gastroenterology|July 18, 2023
P035 Ozanimod for Moderate-to-Severe Ulcerative Colitis: North American Population Results During Induction and Maintenance in the Phase 3 True North StudyDavid Hudesman, Millie Long, Douglas Wolf, et al.
The American Journal of Gastroenterology|July 18, 2023
P038 Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple SclerosisMillie Long, Raymond Cross, Jonathan Calkwood, et al.
Gastroenterology|April 14, 2019
Inflammatory Bowel Disease Care Referral PathwayJami Kinnucan, David Binion, Raymond Cross, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 6, 2014
Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitisMark T Osterman, Faten N Aberra, Raymond Cross, et al.
Inflammatory Bowel Diseases|March 15, 2020
Endoscopic and Histological Assessment, Correlation, and Relapse in Clinically Quiescent Ulcerative Colitis (MARQUEE)Mark T Osterman, Frank I Scott, Franz F Fogt, et al.
Alimentary Pharmacology & Therapeutics|August 4, 2020
A phase 2B randomised trial of hyperbaric oxygen therapy for ulcerative colitis patients hospitalised for moderate to severe flaresParambir S Dulai, Laura E Raffals, David Hudesman, et al.
Alimentary Pharmacology & Therapeutics|November 15, 2022
Crohn's disease shared decision making intervention leads to more patients choosing combination therapy: a cluster randomised controlled trialYaara Zisman-Ilani, Kimberly D Thompson, Lori S Siegel, et al.
Inflammatory Bowel Diseases|August 26, 2021
The Development and Initial Findings of A Study of a Prospective Adult Research Cohort with Inflammatory Bowel Disease (SPARC IBD)Laura E Raffals, Sumona Saha, Meenakshi Bewtra, et al.
The Lancet. Gastroenterology & Hepatology|January 20, 2020
Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease GroupBo Shen, Gursimran Kochhar, Udayakumar Navaneethan, et al.
Pageof 2